Throughout the study, especially during Cycles 1 and 2, patients will undergo frequent blood and urine tests, procedures to assess safety including heart function, and tests to assess the course of the patient's illness. Two weeks after the last dose of the study drug, patients are required to return to the study site for follow-up assessments. R306465 will be administered orally once daily for 21 consecutive days followed by a 1-week rest period. These 4 weeks will constitute 1 treatment cycle. The starting dose level will be 100mg. The dose for each patient will be assigned at enrollment. On the basis of assessment by the investigator, the patient may continue to receive study drug as long as there is clinical benefit and in absence of intolerable side effects.